VolitionRX Ltd (VNRX)

VolitionRx enacted a one-for-twenty reverse stock split on April 29, 2026. NYSE American accepted the company's compliance plan after a notice of non-compliance. Volition announced a breakthrough in finger-prick detection of nucleosomes and submitted a manuscript for its Nu.Q® Vet Cancer Test in cats. The company launched its rNuQ™ Webshop and announced its full fiscal year 2025 financial results, reporting increased revenue but also significant losses and a "going concern" audit opinion. A Mayo Clinic study demonstrated elevated Nu.Q® concentrations in trauma patients, and Volition secured EUR 2.0 million in non-dilutive funding. Analysts have a consensus rating of "Moderate Buy" with a high price target, although some have decreased their targets. The stock price has decreased by 56.0% since the start of 2026.

There is no explicit mention of demand seasonality for VolitionRx Ltd.'s products and services. Demand is likely driven by disease prevalence and healthcare needs rather than seasonal factors.

VolitionRx Limited is a multi-national epigenetics company focused on developing and commercializing nucleosome-based blood tests for early disease detection and monitoring in humans and animals. The company operates in the Healthcare sector, specifically in Medical Devices, In Vitro & in Vivo Diagnostic Substances, and Biotechnology & Drugs. Its core technology is the Nu.Q® platform, which measures nucleosome biomarkers. Key products include Nu.Q® Cancer assays for lung cancer management, Nu.Q® NETs assays for NETosis-associated conditions, Capture-Seq™ for cancer testing, a High Throughput NETs method, and Veterinary Diagnostics, including the Nu.Q® Vet Cancer Test for dogs and a feline assay under development.

VolitionRx Limited is incorporated in Delaware and has its principal executive offices in Henderson, Nevada. The company has a global presence with R&D in Belgium, an innovation lab and office in the United States, and offices in London and Singapore. It also has subsidiary operations and strategic partnerships across the United States, Europe, and Asia.

VolitionRx's brand reputation has been influenced by positive clinical and commercial advancements as well as financial challenges. Positive developments include the inclusion of Nu.Q® NETs assay in a sepsis detection program, progress in lung cancer management, success in veterinary diagnostics, strategic partnerships, and innovation with the Capture-Seq™ platform. Negative factors impacting reputation include a "going concern" audit opinion, NYSE American listing non-compliance, and a stock price decline.

VolitionRx has a mixed ownership structure including institutional, insider, and retail investors. Institutional shareholders hold approximately 1.79% to 10.19% of the stock, with major holders including Lagoda Investment Management, L.P., and Vanguard Group Inc. Insiders own approximately 9.74% to 25.62% of the stock, with Eight Corp Ltd being the largest individual shareholder. Retail investors hold a significant portion, estimated at 64.19% to 88.47% of the stock.